Pilot Decentralized Trial

Alto Neuroscience

Status and phase: Completed; Phase 2

Conditions: Major Depressive Disorder

Treatments: Drug: ALTO-100 PO Tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT05419869

ALTO-100-003

Details and patient eligibility

About

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.

Enrollment: 21 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a diagnosis of moderate to severe major depressive disorder
• Either currently taking a SSRI, SNRI, mirtazapine, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks, or are not taking an antidepressant medication
• Willing to comply with all study assessments and procedures
• Must not be pregnant or breastfeeding at time of enrollment or throughout study
• Must have access with privacy to a computer with a keyboard and internet

Exclusion criteria

• Evidence of acute or unstable cardiovascular, respiratory, hepatic, or other major disease
• Active suicidal ideation
• Severe impediment to vision, hearing, and/or hand movement
• Diagnosed bipolar disorder or psychotic disorder
• Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients
• Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

ALTO-100

Experimental group

Description:

ALTO-100 tablet PO ; twice daily dosing 8 weeks

Treatment:

Drug: ALTO-100 PO Tablet